Transdifferentiating Liver Cells Into Insulin-Producing Beta Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for insulin-dependent diabetes mellitus (IDDM) rely on inconvenient and imprecise self-injection of insulin, and alternative methods like islet or pancreas transplantation face challenges such as low donor tissue availability, enzymatic damage, and immune rejection, highlighting the need for improved procedures for isolating and transdifferentiating non-pancreatic cells for therapeutic use.
Innovation Solution
A method for manufacturing human insulin-producing cells by obtaining adult human liver tissue, processing it to recover primary cells, propagating and expanding them, and transdifferentiating them using adenoviral vectors encoding pancreatic transcription factors like PDX-1, NeuroD1, and MafA, resulting in cells that secrete insulin in a glucose-regulated manner, which can be used for transplant therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If islet or pancreas transplantation is used to treat IDDM, then insulin replacement can be achieved, but donor tissue availability is low and immune rejection occurs
Solution Approach 1:
The patent uses adenoviral vectors as intermediaries to deliver pancreatic transcription factor genes (PDX-1, NeuroD1, MafA) into non-pancreatic cells, enabling transdifferentiation into insulin-producing cells without requiring actual pancreatic islet transplants, thus resolving the donor tissue availability limitation
Solution Approach 2:
The patent changes the cellular parameters by introducing exogenous transcription factors that alter the gene expression profile of non-pancreatic cells, transforming them into functional beta-like cells that produce and secrete insulin in response to glucose, thereby creating an alternative source of insulin-producing cells
2Reliability
If islet or pancreas transplantation is used to treat IDDM, then insulin replacement can be achieved, but immune rejection occurs
Solution Approach 1:
The patent uses non-pancreatic cells (such as fibroblasts or epithelial cells) as intermediaries that are transdifferentiated into insulin-producing cells, rather than using actual pancreatic islets. This alternative cellular origin may reduce immune recognition and rejection while maintaining insulin production functionality
Solution Approach 2:
The patent creates functional copies of beta cell functionality by introducing transcription factors that replicate the gene expression program of pancreatic beta cells in non-pancreatic cells, producing cells that mimic beta cell behavior without being actual pancreatic tissue, potentially avoiding immune rejection of pancreatic antigens
3Quantity of substance
If enzymatic isolation of islets is performed, then islet cells can be obtained, but enzymatic and physical damage occurs
Solution Approach 1:
Instead of isolating islet cells from pancreatic tissue through enzymatic digestion, the patent inverts the approach by transforming non-pancreatic cells into insulin-producing cells through genetic transdifferentiation, completely avoiding the harmful enzymatic isolation process
Solution Approach 2:
The patent converts the limitation of using non-pancreatic cells (which normally cannot produce insulin) into a benefit by using these cells as a damage-free source for generating insulin-producing cells through transdifferentiation, avoiding all the damage associated with islet isolation
4Reliability
If self-injection of insulin is used to treat IDDM, then insulin replacement can be achieved, but treatment is inconvenient and imprecise
Solution Approach 1:
The patent creates insulin-producing cells that autonomously sense glucose levels and secrete insulin in response, eliminating the need for patient self-injection and manual insulin dosing decisions, as the transdifferentiated cells perform the insulin secretion function automatically based on physiological glucose levels
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces a population of human insulin-producing cells with increased insulin content and glucose-regulated secretion, offering a promising alternative to traditional insulin treatments by providing a stable and efficient source of autologous or allogeneic cells for diabetes therapy.
Implementation Method 1
transdifferentiating them using adenoviral vectors encoding pancreatic transcription factors like PDX-1, NeuroD1, and MafA
Data Source
AI summary
Disclosed herein is a method for manufacturing a population of human insulin producing cells from non-pancreatic β-cells, wherein the resulting insulin producing cells have increased insulin content, or increased glucose regulated secretion of insulin, or a combination of both.